ICON plc (NASDAQ: ICLR) is well-poised to grow in the coming quarters, driven by its meaningful strategic additions. The company is committed to improving patient access and engagement strategy. Meanwhile, concerns about the adverse macroeconomic impacts as well as currency fluctuations remain, which may hamper ICON's performance.
In the past year, this Zacks Rank #3 (Hold) company has gained 27% compared with the industry's 9.9% growth and 27.1% rise of the S&P 500 composite.
The leading healthcare intelligence and clinical research organization has a market capitalization of $26.85 billion. The company's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.92%.
Let's delve deeper.
Tailwinds
Focus on Patient Access & Engagement Strategy: ICON is continuously improving in site identification, study placement and patient recruitment and retention through its focused patient, site and data strategy.
In line with this, Accellacare, ICON's global clinical research network, is offering customers a wide range of stand-alone and integrated solutions at the site or in patients' homes as part of decentralized trials. One of the key strategic moves of ICON in 2024 was a focused rebranding of its specialized biotech solutions division, ICON Biotech.
During the second quarter of 2024, the company experienced ...
